St Stephens Aids Trust
46
0
0
32
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
10.9%
5 terminated/withdrawn out of 46 trials
86.5%
-0.0% vs industry average
35%
16 trials in Phase 3/4
9%
3 of 32 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (46)
Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy
Role: lead
The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers
Role: lead
Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)
Role: lead
SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
Role: lead
Progesterone and Aminophylline for the Prevention of Preterm Labour
Role: lead
Pharmacokinetic Effect of Evotaz/Microgynon Co-administration
Role: lead
SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins
Role: lead
SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women
Role: lead
SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
Role: lead
PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation
Role: lead
A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
Role: lead
Renal Integrase Study
Role: lead
The Pharmacology/Aging Clinic
Role: lead
Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
Role: lead
Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
Role: lead
A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
Role: lead
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
Role: lead
PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers
Role: lead
SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers
Role: lead
SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat
Role: lead